Skip to main content
Bachem Holding AG logo

Bachem Holding AG — Investor Relations & Filings

Ticker · BANB ISIN · CH1176493729 LEI · 506700S81111XI7TG884 SW Manufacturing
Filings indexed 28 across all filing types
Latest filing 2026-05-05 Board/Management Inform…
Country CH Switzerland
Listing SW BANB

About Bachem Holding AG

https://www.bachem.com/

Bachem is a technology company specializing in the development and manufacturing of peptides and oligonucleotides. As a contract development and manufacturing organization (CDMO), it provides a comprehensive range of products and services to the pharmaceutical and biotechnology industries. The company supports clients throughout the entire product lifecycle, from research and clinical development to commercial application. Its portfolio includes active pharmaceutical ingredients (APIs) as New Chemical Entities (NCEs) and generics, as well as an extensive catalog of research-grade products such as catalog peptides, amino acid derivatives, and custom synthesis services. Bachem also offers its expertise for cosmetic and diagnostic applications.

Recent filings

Filing Released Lang Actions
Bachem announces changes to the Corporate Executive Committee
Board/Management Information Classification · 100% confidence The document is a media release announcing changes to the Corporate Executive Committee of Bachem Holding AG, specifically the departure of the Chief Commercial Officer and the temporary assumption of his role by the CEO. There is no financial data, no mention of a report or filing, and the content focuses solely on management changes. This fits the category of Board/Management Information (MANG). The document length is short and it is clearly an announcement, not a report or transcript.
2026-05-05 English
Bachem gibt Änderungen in der Konzernleitung bekannt
Board/Management Information Classification · 100% confidence The document is a media release dated May 5, 2026, from Bachem Holding AG announcing a change in the company's executive management: the Chief Commercial Officer is leaving and the CEO will temporarily take over the role. The text focuses on management changes and does not contain financial data, report attachments, or references to financial results. It is not a full report, earnings release, or regulatory filing. The content fits the category of announcements about changes in the company's board or senior management.
2026-05-05 German
Bachem Annual General Meeting 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a post-AGM media release summarizing the voting results of the Annual General Meeting 2026: approval of board proposals, dividend declaration, election of directors, auditor appointment, and details on vote tallies. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-04-29 English
Bachem - Ordentliche Generalversammlung 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release summarizing the results of the 2026 Ordinary General Meeting of Bachem Holding AG. It lists approvals of board proposals, votes cast, dividend resolution, board member elections, and other AGM decisions. This matches the category for official results from shareholder votes at a general meeting, i.e., Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-29 German
Bachem secures financing of strategic growth initiatives
Capital/Financing Update Classification · 90% confidence The document is a media release announcing the closing of a CHF 500 million revolving credit facility to support strategic growth initiatives. It details the financing terms, syndication banks, and purpose of the facility, which aligns with a Capital/Financing Update rather than a full report or regulatory filing.
2026-04-27 English
Bachem sichert Finanzierung strategischer Wachstumsinitiativen
Capital/Financing Update Classification · 92% confidence The document is a media release announcing the closing of a CHF 500 million revolving credit facility (with an option for CHF 150 million) syndicated by banks, including commentary from the CFO on refinancing bilaterial lines and supporting strategic growth initiatives. This is a direct update on the company’s financing activities and capital structure, fitting the Capital/Financing Update category.
2026-04-27 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.